Spark Therapeutics (ONCE) Misses Q2 EPS by 66c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Spark Therapeutics Reports Second Quarter 2017 Financial Results and Recent Business Progress
August 2, 2017 7:30 AM EDTPreliminary interim data for SPK-8011 Phase 1/2 dose-escalation clinical trial in hemophilia A show initial human proof-of-concept in three participants
In the two participants at the initial dose, stable factor VIII levels average greater than 12 percent with no spontaneous bleeds
Investigational LUXTURNATM (voretigene neparvovec) Prescription Drug User Fee Act (PDUFA) date set for Jan. 12, 2018; granted rare pediatric disease designation by FDA
PHILADELPHIA, Aug. 02, 2017 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ: ONCE), a fully integrated gene therapy company dedicated to... More
